{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide+1+receptor+agonist", "query": { "intervention": "Glucagon-like peptide 1 receptor agonist" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 160, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide+1+receptor+agonist&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T16:19:32.960Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07091734", "title": "Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lipodystrophy, Partial" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Usual care medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2025-09-08", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07091734" }, { "nct_id": "NCT07547878", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Lotensin", "type": "DRUG" }, { "name": "Capoten", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Monopril", "type": "DRUG" }, { "name": "Lisinopril", "type": "DRUG" }, { "name": "Univasc", "type": "DRUG" }, { "name": "Aceon", "type": "DRUG" }, { "name": "Accupril", "type": "DRUG" }, { "name": "Altace", "type": "DRUG" }, { "name": "Mavik", "type": "DRUG" }, { "name": "Edarbi", "type": "DRUG" }, { "name": "Atacand", "type": "DRUG" }, { "name": "Avapro", "type": "DRUG" }, { "name": "Cozaar", "type": "DRUG" }, { "name": "Benicar", "type": "DRUG" }, { "name": "Micardis", "type": "DRUG" }, { "name": "Diovan", "type": "DRUG" }, { "name": "Invokana", "type": "DRUG" }, { "name": "Farxiga", "type": "DRUG" }, { "name": "Jardiance", "type": "DRUG" }, { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Brenzavvy", "type": "DRUG" }, { "name": "Sotagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 64, "start_date": "2026-04-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "nct_id": "NCT07554417", "title": "Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "GLP - 1", "Obesity & Overweight", "Muscle Loss", "Exercise Intervention", "Dietary Assessment" ], "interventions": [ { "name": "Semaglutide", "type": "DRUG" }, { "name": "Dietary Counseling", "type": "BEHAVIORAL" }, { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "William Marsh Rice University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "40 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2026-04-06", "completion_date": "2026-08-06", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07554417" }, { "nct_id": "NCT03331289", "title": "Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Exenatide", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Exenatide and Dapagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 107, "start_date": "2018-02-28", "completion_date": "2022-11-04", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03331289" }, { "nct_id": "NCT06901245", "title": "Tirzepatide in PWS, HO and GNSO", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Prader-Willi Syndrome", "Hypothalamic Obesity", "Obesity/Therapy" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grace Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "26 Years", "sex": "ALL", "summary": "18 Years to 26 Years" }, "enrollment_count": 36, "start_date": "2025-05-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 3, "location_summary": "Saint Paul, Minnesota • Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06901245" }, { "nct_id": "NCT06518837", "title": "Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor-Positive Breast Cancer", "HER2-Negative Breast Cancer" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-10-30", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 7, "location_summary": "Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more", "locations": [ { "city": "Elizabeth", "state": "New Jersey" }, { "city": "Hamilton", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518837" }, { "nct_id": "NCT07702461", "title": "Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Obesity & Overweight", "Diabetes (DM)" ], "interventions": [ { "name": "Glucagon-Like Peptide-1 Agonist (GLP-1)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2026-06-12", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07702461" }, { "nct_id": "NCT06732245", "title": "Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity and Overweight" ], "interventions": [ { "name": "NA-931", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" }, { "name": "NA-931 150 mg + no Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biomed Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "19 Years to 80 Years" }, "enrollment_count": 224, "start_date": "2026-08-15", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 8, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06732245" }, { "nct_id": "NCT06996886", "title": "A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD5004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2025-05-22", "completion_date": "2025-07-25", "has_results": false, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06996886" }, { "nct_id": "NCT03987919", "title": "A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1879, "start_date": "2019-07-30", "completion_date": "2021-02-15", "has_results": true, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-10-09T16:19:32.960Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Huntington Park", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03987919" } ] }